Followers | 376 |
Posts | 18023 |
Boards Moderated | 3 |
Alias Born | 04/29/2015 |
Wednesday, July 26, 2017 9:20:15 AM
Recent RGLS News
- Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates • PR Newswire (US) • 03/21/2024 08:05:00 PM
- Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity • PR Newswire (US) • 03/12/2024 10:32:00 AM
- Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 03/12/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 01:24:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 01:23:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:08:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:04:34 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/12/2024 09:11:34 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/10/2024 05:15:20 AM
- Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 01/02/2024 09:05:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/27/2023 09:16:06 PM
- Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference • PR Newswire (US) • 11/22/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:39:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:15:35 PM
- Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates • PR Newswire (US) • 11/09/2023 09:05:00 PM
- Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 11/02/2023 12:00:00 PM
- Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 10/19/2023 12:00:00 PM
- Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 09/20/2023 11:00:00 AM
- Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 09/13/2023 12:00:00 PM
- Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences • PR Newswire (US) • 09/05/2023 12:00:00 PM
- Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023 • PR Newswire (US) • 08/23/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:40:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:36:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:34:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:21:39 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM